OP14 – Hyperthyroidism and thyroid cancer: Report of 91 cases and review of the literature

     

    de Rienzo-Madero, Beatriz1; Amichaud, Regis1; Kraimps, Jean Louis1; Donatini, Gianluca1
    1 Department of Endocrine Surgery, University Hospital of Poitiers, Poitiers, France

     


    Background/ Purpose: 
    Hyperthyroidism has been considered a protective factor for thyroid cancer. However, in the literature, an association between these two entities ranges up to 18.3%.  We describe the prevalence of thyroid cancer within hyperthyroid patients who underwent surgery at our institution.

    Methods: A review of patients who underwent surgery between January 1991 and January 2015 was performed. Variables analyzed were: sex, age, clinico-biological characteristics, histology, disease extension, and type of surgical procedure. Malignancy was confirmed with final histopathology.

    Results: Overall, 11140 patients underwent thyroidectomy; 1236 (11.09%) patients had hyperthyroidism, and 91 of these (7.6%) had an associated thyroid carcinoma. Fifty-one patients (56.0%) had toxic multinodular goiter, 32 (35.2%) Grave’s disease and 8 (8.8%) solitary toxic adenoma. Nine patients (9.9%) required associated lymph node dissection.  Cancer types were: classic papillary carcinoma in 80 patients (87.9%), follicular carcinoma in 7 (7.7%), follicular variant of papillary carcinoma in 3 patients (3.3%) and 1 medullary carcinoma (1.1%). Fourteen patients had multifocal cancer. Six of the 9 patients with lymph node extension had Graves’s disease. No distant metastasis were observed.

    Conclusion: Hyperthyroidism is not a protective factor for thyroid cancer as evidenced by the same prevalence of cancer in all patients undergoing thyroidectomy (p>0.05). Our findings confirm the prevalence reported in current literature data. Thyroid cancer in Grave’s disease patients seems to be more aggressive as it shows a higher prevalence of lymph nodes metastasis compared to other subgroups of hyperthyroidism associated cancer. FNA cytology should be performed on nodular Grave’s disease.

 

Leave a Reply

  • Upcoming Events

     

    World Congress on Thyroid Cancer 3.5
    Rome, Italy | 2019

    World Congress on Thyroid Cancer 4.0
    July 29 – August 1, 2021
    Boston, Massachusetts

     

  • WCTC3.5 Steering Committee:

     

    Rocco Bellatone, Co-Chair
    Celestino Lombardi, Co-Chair
    Gregory W. Randolph, MD
    Bryan McIver, MD
    Jeremy Freeman, MD
    Ian J. Witterick, MD
    Ashok R. Shaha, MD
    Jatin P. Shah, MD